logo
Share SHARE
FONT-SIZE Plus   Neg

Strides Arcolab Gets US FDA Nod For Vancomycin Oral Capsules

Strides Arcolab Ltd. said it had received approval from the US FDA to market its generic Vancomycin Hydrochloride capsules in the strength of 125mg and 250 mg.

Vancomycin capsules is glycopeptides antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. It has traditionally been reserved as a drug of last resort, used only after treatment with other antibiotics had failed.

The company plans to launch the product immediately through US-based Alvogen on a profit-sharing basis, the company said.

As per IMS health data, Vancomycin capsules had total US sales of $332 million for the twelve months ended February 12, with no prior generic approvals.

Commenting on the development, Strides Group CEO Arun Kumar said, "Oral Vancomycin development is one among the many value generics programmes being undertaken at the Strides Group with a special focus to develop niche and difficult-to-manufacture products.''

At the BSE, Strides Arcolab closed Wednesday's trading at Rs 631.90, after touching a 52-week high of Rs.649 in the early trading session.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

0 Articles
Editors Pick
Is it a 'personal life crisis' that led the Germanwings' co-pilot Andreas Lubitz to deliberately lowering the plane carrying 149 people to French Alps mountain? Police is investigating to find evidences to prove this suggestion. The Germanwings plane crash has spurred European airlines to implement stringent cockpit rules widely followed in the U.S., after it emerged a lone co-pilot forced the plane into its fatal descent, reports said on Thursday. Video-game retailer GameStop Corp. said Thursday after the markets closed that its fourth quarter profit rose 11% from last year, as better cost control helped offset a 5.6% decrease in sales. However, the company's quarterly earnings per share, excluding item, came in below analysts' expectations as did its quarterly sales.
comments powered by Disqus
Follow RTT